Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma

被引:0
作者
Tetsushi Murakami
Nobuyuki Tanaka
Kimiharu Takamatsu
Kyohei Hakozaki
Keishiro Fukumoto
Tsukasa Masuda
Shuji Mikami
Toshiaki Shinojima
Kazuhiro Kakimi
Tatsuhiko Tsunoda
Kazuaki Sawada
Takeshi Imamura
Ryuichi Mizuno
Mototsugu Oya
机构
[1] Keio University School of Medicine,Department of Urology
[2] Keio University Hospital,Department of Diagnostic Pathology
[3] Saitama Medical University,Department of Urology
[4] The University of Tokyo Hospital,Department of Immunotherapeutics
[5] The University of Tokyo,Laboratory for Medical Science Mathematics, Department of Biological Sciences, Graduate School of Science
[6] Medical Research Institute,Department of Medical Science Mathematics
[7] Tokyo Medical and Dental University (TMDU),Laboratory for Medical Science Mathematics
[8] RIKEN Center for Integrative Medical Sciences,Center for Integrated Medical Research
[9] Keio University School of Medicine,Department of Molecular Medicine for Pathogenesis, Graduate School of Medicine
[10] Ehime University,undefined
来源
Cancer Immunology, Immunotherapy | 2021年 / 70卷
关键词
Renal cell carcinoma; Kidney; CD8; CD39; PD-1; Single cell; Heterogeneity;
D O I
暂无
中图分类号
学科分类号
摘要
Despite the high sensitivity of renal cell carcinoma (RCC) to immunotherapy, RCC has been recognized as an unusual disease in which CD8+ T-cell infiltration into the tumor beds is related to a poor prognosis. To approach the inner landscape of immunobiology of RCC, we performed multiplexed seven-color immunohistochemistry (CD8, CD39, PD-1, Foxp3, PD-L1, and pan-cytokeratin AE1/AE3 with DAPI), which revealed the automated single-cell counts and calculations of individual cell-to-cell distances. In total, 186 subjects were included, in which CD39 was used as a marker for distinguishing tumor-specific (CD39+) and bystander (CD39−) T-cells. Our clear cell RCC cohort also revealed a poor prognosis if the tumor showed increased CD8+ T-cell infiltration. Intratumoral CD8+CD39+ T-cells as well as their exhausted CD8+CD39+PD-1+ T-cells in the central tumor areas enabled the subgrouping of patients according to malignancy. Analysis using specimens post-antiangiogenic treatment revealed a dramatic increase in proliferative Treg fraction Foxp3+PD-1+ cells, suggesting a potential mechanism of hyperprogressive disease after uses of anti-PD-1 antibody. Our cell-by-cell study platform provided spatial information on tumors, where bystander CD8+CD39− T-cells were dominant in the invasive margin areas. We uncovered a potential interaction between CD8+CD39+PD-1+ T-cells and Foxp3+PD-1+ Treg cells due to cell-to-cell proximity, forming a spatial niche more specialized in immunosuppression under PD-1 blockade. A paradigm shift to the immunosuppressive environment was more obvious in metastatic lesions; rather the infiltration of Foxp3+ and Foxp3+PD-1+ Treg cells was more pronounced. With this multiplexed single-cell pathology technique, we revealed further insight into the immunobiological standing of RCC.
引用
收藏
页码:3001 / 3013
页数:12
相关论文
共 102 条
[1]  
Kim JM(2016)Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) Ann Oncol 27 1492-1504
[2]  
Chen DS(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028
[3]  
Garon EB(2014)Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 2189-2199
[4]  
Rizvi NA(2017)Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 389 255-265
[5]  
Hui R(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813
[6]  
Snyder A(2018)Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-1290
[7]  
Makarov V(2019)Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger Ann Oncol 30 706-720
[8]  
Merghoub T(2019)European association of urology guidelines on renal cell carcinoma: the 2019 update Eur Urol 75 799-810
[9]  
Rittmeyer A(2019)NCCN guidelines insights: kidney cancer version 2 J Natl Compr Canc Netw 17 1278-1285
[10]  
Barlesi F(2018)The immunobiology of kidney cancer J Clin Oncol 36 3547-3552